^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Loqtorzi (toripalimab-tpzi)

    i
    Other names: JS001, JS-001, JS 001, TAB-001, TAB001, terepril monoclonal antibody, treipril monoclonal antibody, TAB 001
    Company:
    Apotex, Coherus Oncology, Dr. Reddy’s, Excellmab, Hikma, LEO Pharma, Shanghai Junshi Biosci
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=148, Recruiting, Sun Yat-sen University | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Loqtorzi (toripalimab-tpzi)
    1d
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial (clinicaltrials.gov)
    P3, N=212, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • Loqtorzi (toripalimab-tpzi)
    1d
    TRIPLE-PATH: Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=75, Recruiting, Jinling Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    1d
    Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sun Yat-sen University | Trial completion date: Dec 2025 --> May 2026
    Trial completion date
    |
    cisplatin • Loqtorzi (toripalimab-tpzi)
    2d
    TPLM: Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Guangzhou Medical University | Trial primary completion date: Jan 2026 --> Jul 2026
    Trial primary completion date • Checkpoint inhibition
    |
    Loqtorzi (toripalimab-tpzi) • pemetrexed
    2d
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=400, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    4d
    Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=480, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • AWT020
    6d
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients (clinicaltrials.gov)
    P3, N=212, Recruiting, Sun Yat-sen University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    cisplatin • Loqtorzi (toripalimab-tpzi)
    6d
    Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy (clinicaltrials.gov)
    P1, N=6, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi)
    7d
    TRIPLE-PATH: Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Jinling Hospital, China
    New P2 trial
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    7d
    A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma (PubMed, Zhonghua Zhong Liu Za Zhi)
    Patients received combination therapy with nab-paclitaxel, bevacizumab, and toripalimab (Q3W) at Nanjing Drum Tower Hospital. Furthermore, this triplet therapy combined with radiotherapy significantly improves PFS. Preliminary biomarker analysis suggests that patients with liver metastasis, MET or NF1 mutations may be less likely to benefit from this treatment regimen.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • NF1 (Neurofibromin 1)
    |
    MET mutation
    |
    Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    11d
    LIGHT: LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC (clinicaltrials.gov)
    P2, N=55, Recruiting, Sun Yat-sen University | Trial completion date: Jun 2028 --> Jan 2030 | Trial primary completion date: Sep 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Loqtorzi (toripalimab-tpzi)